FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
WEBJun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
Experimental Alzheimer's drug donanemab outperforms Leqembi in ... - NPR
WEBJul 17, 2023 · In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
News Release - Eli Lilly and Company
WEBJul 2, 2024 · Kisunla™ (donanemab-azbt) (pronounced kih-SUHN-lah) is an amyloid-targeting treatment for people with mild cognitive impairment (MCI) as well as people with mild dementia stage of early symptomatic Alzheimer's …
FDA approves donanemab, Eli Lilly’s treatment for early ... - CNN
WEBJul 2, 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
Second Alzheimer’s drug to slow disease’s progression may be ... - CNN
WEBJul 17, 2023 · A second drug may join the Alzheimer’s treatment Leqembi on the market by the end of the year: Eli Lilly’s donanemab. Lilly said in a news release that it had completed its US Food and Drug ...
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 · The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
Donanemab in Early Alzheimer’s Disease | NEJM
WEBMar 13, 2021 · Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer’s disease. Methods. We conducted a phase 2 trial of donanemab in...
Alzheimer’s drug donanemab helps most when taken at earliest
WEBJul 17, 2023 · Like many others in the newest generation of Alzheimer’s drugs, donanemab is a monoclonal antibody that targets amyloid, a sticky, neuron-damaging protein, in the brains of people with dementia.
Alzheimer’s drug donanemab: what promising trial means for
WEBMay 4, 2023 · Alzheimer’s drug donanemab: what promising trial means for treatments. Results suggest that the amyloid-targeting drug candidate slows cognitive decline in some people, but questions remain over...